Answers are grounded in this paper and cite their sources.
BackgroundPediatric alopecia areata (AA) is an immune-mediated hair loss disorder associated with substantial psychosocial burden and limited treatment options.Evidence regarding the effectiveness and safety of baricitinib in children remains limited. ObjectiveTo evaluate the real-world effectiveness and laboratory safety outcomes of oral baricitinib in Saudi pediatric patients with AA. MethodsThis retrospective cohort study included 38 pediatric patients treated with oral baricitinib at King Fahad Medical City, Riyadh, Saudi Arabia, between January 2018 and December 2024.Demographic characteristics, previous treatments, dosing regimens, clinical outcomes, and laboratory findings were extracted from electronic medical records.Treatment outcomes were categorized as complete response, partial response, ineffective treatment, or no response.Associations between clinical characteristics and treatment outcomes were assessed using chi-square or Fisher's exact tests. ResultsThe mean patient age was 12.24 ± 3.34 years, and 19 patients (50.0%) were female.Twenty patients (52.6%) had previously received tofacitinib.The median starting and optimal baricitinib doses were 2 mg and 4 mg, respectively, and the median treatment duration was 12 months.Complete and partial responses were documented in 11 (28.9%) and 22 (57.9%)patients, respectively, yielding a combined response proportion of 86.8%.One patient (2.6%) was classified as having ineffective treatment, and four (10.5%) had no response.At or after three months, abnormal low-density lipoprotein levels, liver function tests, and glomerular filtration rate were recorded in 19 (50.0%), 12 (31.6%),and two (5.3%) patients, respectively.Treatment outcomes were not significantly associated with sex or previous tofacitinib exposure. ConclusionBaricitinib was associated with complete or partial clinical responses in most patients in this pediatric cohort.Laboratory abnormalities highlight the importance of ongoing monitoring.Larger prospective studies using standardized response definitions and longer follow-up are needed to establish pediatric effectiveness and long-term safety.
No takes yet. Share an insight, caveat, or question.
Aleidi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: